Stock Details
4519.T is Chugai Pharmaceutical Co., Ltd.'s stock. Stock exchange Tokyo (Currency JPY). Average price in 50 days is 3,941.40๏ฟฅ. Average daily volumn in 3 months 2.17M. Market cap 5.77T



Stock symbol : 4519.T. Exchange : Tokyo. Currency : JPY
Lastest price : 3,507.00๏ฟฅ. Total volume : 1.88M. Market state PREPRE
Click reload if you want to check the lastest price on market!!!

Chugai Pharmaceutical Co., Ltd. (4519.T)
Last Price
3,507.00๏ฟฅ
Change
-44.00
Volume
1.88M

Previous Close3,551.00
Open3,555.00
Day Range3,504.00-3,565.00
Bid0.00 x N/A
Ask0.00 x N/A
Volume1.88M
Average Volume2.17M
Market Cap5.77T
Beta0.66
52 Week Range3,490.00-4,640.00
Trailing P/E14.90
Foward P/E18.40
Dividend (Yield %)2.14%
Ex-Dividend Date2022-06-29



Financial Details


According to Chugai Pharmaceutical Co., Ltd.'s financial reports the company's revenue in 2021 were 999.76B an increase( +27.1%) over the years 2020 revenue that were of 786.95B. In 2021 the company's total earnings were 303B while total earnings in 2020 were 214.73B( +41.59%).


Loading ...



Organization

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept... , and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Market Cap:
5.77T
Revenue:
999.76B
Total Assets:
1.54T
Total Cash:
267.75B


News about "Chugai Pharmaceutical Co., Ltd."

Chugai Pharmaceutical Co Ltd ADR (CHGCY)

Source from : Investing.com - 2 days ago

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...See details»


Chugai Pharmaceutical Co., Ltd. 2022 Q1 - Results - Earnings Call Presentation

Source from : Seeking Alpha - 1 month ago

Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site ...See details»


Chugai Pharmaceutical (OTCMKTS:CHGCY) vs. BIMI International Medical (NASDAQ:BIMI) Head to Head Analysis

Source from : ETF Daily News - 6 days ago

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of ...See details»


Chugai Pharmaceutical Co Ltd - Stock Executive CHGCF

Source from : Morningstar%2c Inc. - 13 days ago

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.See details»


Chugai Pharmaceutical Co Ltd - Stock Analysis CUP

Source from : Morningstar%2c Inc. - 7 days ago

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...See details»


Chugai Pharmaceutical (OTCMKTS:CHGCY) Downgraded to Hold at Zacks Investment Research

Source from : ETF Daily News - 14 days ago

According to Zacks, โ€œCHUGAI PHARMACEUTICAL CO. LTD. is mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products for treatment of cancer ...See details»


Chugai adopts Snowflake Data Cloud to accelerate use of internal data across company

Source from : Pharmabiz - 1 month ago

Chugai Pharmaceutical Co., Ltd., a research-based pharmaceutical company, and Snowflake announce that Chugai has adopted the Snowflake Data Cloud, a data cloud platform provided by Snowflake. The ...See details»


Chugai Pharmaceutical reports Q1 results

Source from : Seeking Alpha - 1 month ago

Chugai Pharmaceutical press release (OTCPK:CHGCF): Q1 GAAP EPS of ยฅ80.09. Revenue of ยฅ360.6B (+113.6% Y/Y). To ensure this doesnโ€™t happen in the future, please ...See details»


Chugai Pharmaceutical earnings preview: what Wall Street is expecting

Source from : Business Insider - 1 month ago

On April 25, Chugai Pharmaceutical will release earnings for Q1. Wall Street analysts predict earnings per share of ยฅ53.82. Watch Chugai Pharmaceutical stock price in real-time on Markets Insider ...See details»


Mitsubishi Electric Announces Director Candidates

Source from : Associated Press - 22 hours ago

Mitsubishi Electric Corporation (TOKYO Prime Market: 6503) announces that it has received the interim report on the results of the company-wide investigation and assessment on improper quality control ...See details»


autoimmune-therapeutics-market-report-competitive-dynamics-42-healthy-cagr-future-key-trends-global-outlook-2022-to-2029-image

Autoimmune Therapeutics Market Report: Competitive Dynamics, 4.2% Healthy CAGR, Future Key Trends & Global Outlook 2022 to 2029

Source from : Digital Journal - 6 days ago

Introduction The Global Autoimmune Therapeutics Market has seen continuous development in the past couple of years and is ...See details»


Autoimmune Treatment Market Size, Business Revenue Forecast, Leading Competitors and Growth Trends

Source from : Digital Journal - 6 days ago

Autoimmune disease is a medical condition that causes abnormalities in the immune response and triggers damage to the healthy body tissues. The increasing prevalence of autoimmune diseases all ...See details»


Hemophilia A Drug Market Size, Share and Forecast till 2028

Source from : MarketWatch - 1 month ago

Chugai Pharmaceutical Co Ltd,CSL Ltd,DBV Technologies SA,Dimension Therapeutics Inc,EpiVax Inc,Expression Therapeutics LLC,Green Cross Corp,Idogen AB,Immusoft Corp,LFB SA,mAbxience SA. The high ...See details»


Global Osteoporosis Therapeutics Market to Reach $14.2 Billion by 2026

Source from : WFMZ-TV - 1 month ago

Companies: 53 - Players covered include Alergan Plc.; Amgen, Inc.; Chugai pharmaceutical; Daiichi Sankyo Co., Ltd.; Egalet Corporation; Eisai Co., Ltd.; Eli Lilly and ...See details»